Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $140.00 Price Target at Piper Sandler

Ultragenyx Pharmaceutical (NASDAQ:RAREFree Report) had its price objective raised by Piper Sandler from $135.00 to $140.00 in a research report report published on Monday,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

RARE has been the subject of a number of other research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. HC Wainwright restated a “buy” rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $121.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 12th. Finally, Wells Fargo & Company increased their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday, December 20th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $92.29.

Check Out Our Latest Research Report on Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $43.16 on Monday. The business’s fifty day moving average price is $46.09 and its two-hundred day moving average price is $49.63. Ultragenyx Pharmaceutical has a fifty-two week low of $37.02 and a fifty-two week high of $60.37. The stock has a market capitalization of $3.99 billion, a price-to-earnings ratio of -6.67 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RAREGet Free Report) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. During the same quarter in the prior year, the firm earned ($2.23) EPS. The firm’s quarterly revenue was up 42.3% compared to the same quarter last year. Research analysts expect that Ultragenyx Pharmaceutical will post -6.2 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 8,273 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total transaction of $413,650.00. Following the completion of the sale, the chief executive officer now directly owns 2,195,712 shares of the company’s stock, valued at $109,785,600. The trade was a 0.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its position in shares of Ultragenyx Pharmaceutical by 5.5% in the 2nd quarter. Rhumbline Advisers now owns 96,710 shares of the biopharmaceutical company’s stock valued at $3,975,000 after acquiring an additional 5,047 shares during the period. BOKF NA boosted its position in shares of Ultragenyx Pharmaceutical by 23.5% during the second quarter. BOKF NA now owns 8,316 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 1,580 shares in the last quarter. Angeles Investment Advisors LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 49.3% in the 2nd quarter. Angeles Investment Advisors LLC now owns 6,640 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 2,193 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in shares of Ultragenyx Pharmaceutical by 38.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 370,247 shares of the biopharmaceutical company’s stock valued at $15,217,000 after buying an additional 103,280 shares during the period. Finally, Amalgamated Bank increased its position in shares of Ultragenyx Pharmaceutical by 13.4% in the 2nd quarter. Amalgamated Bank now owns 5,896 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 696 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

(Get Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Recommended Stories

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.